Amgen Inc.

Martin J Harrison

Frank Kayser

Rajiv Sharma

Christopher Neil Farthing

Sarah Lively

Jinqian Liu

Stephen J Shuttleworth

Alexander David Frenkel

David Craig McGowan

Xiaotian Zhu

David John Kopecky

Erin F DiMauro

John Laird Buchanan

XianYun Jiao

William H Buckner

Teresa L Marshall

Simon A Burkitt

Paul Faulder

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

Furanopyrimidines

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity

Growing community of inventors

Stockport, United Kingdom

Martin J Harrison